People · Operator

Carlos Camozzi

Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology

1
Companies
2
Filings
$6.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
BirchBioMed Inc.BiotechnologySeries A$6.5M$571K2025
Operator network

Carlos Camozzi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Mark Miller · 18 companies · 1 sharedMark MillerHerve Girsault · 2 companies · 1 sharedHerve GirsaultJOSEPH C. SARDANO · 2 companies · 1 sharedJOSEPH C. SARDANORichard J. Shaw · 2 companies · 1 sharedRichard J. ShawTeresa Bair · 2 companies · 1 sharedTeresa BairCharles Ellis · 1 companies · 1 sharedCharles EllisCharles N. Ellis · 1 companies · 1 sharedCharles N. EllisJohn Verbeck · 1 companies · 1 sharedJohn VerbeckJon M. Verbeck · 1 companies · 1 sharedJon M. VerbeckJoseph Sardano · 1 companies · 1 sharedJoseph SardanoMark S. Miller · 1 companies · 1 sharedMark S. MillerRyan V. Hartwell · 1 companies · 1 sharedRyan V. HartwellSusan Elliott · 1 companies · 1 sharedSusan ElliottSusan M. Elliott · 1 companies · 1 sharedSusan M. ElliottTeresa S. Bair · 1 companies · 1 sharedTeresa S. BairBirchBioMed Inc. · $6.5M raisedBirchBioMed Inc.Carlos CamozziCC
Carlos Camozzi Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Carlos Camozzi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Mark Miller118
Richard J. Shaw12
Teresa Bair12
Herve Girsault12
JOSEPH C. SARDANO12
John Verbeck11
Charles Ellis11
Susan Elliott11
Jon M. Verbeck11
Charles N. Ellis11
Teresa S. Bair11
Susan M. Elliott11
Ryan V. Hartwell11
Mark S. Miller11
Joseph Sardano11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.